Hims Pulls GLP-1 Weight Loss Pill Two Days After Announcing It

On Feb. 5, Hims & Hers announced it would be adding a new item to its repertoire. In addition to offering injectable GLP-1 semaglutide drugs for weight loss, the company stated it would also offer a pill version of the same drug. Per a press release, the new offering, a compounded pill with the same active ingredient as Wegovy, would be available at an introductory price of $49 for the first month.

Just two days later, Hims totally backtracked. Now, Reuters reports that the company is pulling the pill. "Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry," Hims said in a statement. "As a result, we have decided to stop offering access to this treatment."

What happened? A whole lot of drama.

FDA Came Down Hard on Hims

Hims' GLP-1 pill wasn't name brand Wegovy. Rather, it was a compounded pill with the same active ingredient. This means Hims specially formulated its own version. Think of it like this: You love meatballs, but you found out you're allergic to gluten, so you formulated a different meatball recipe without breadcrumbs. Beef is still the main ingredient, but the supporting characters are a little different.

While compounded drugs are legal, they are not approved by the FDA. The day after Hims' announcement, the FDA came down hard, announcing it would restrict access to necessary ingredients and refer the company to the Department of Justice to investigate any potential legal violations, per Reuters. This came just a few months after the FDA gave the company a warning over the marketing of its GLP-1 offerings.

Novo Nordisk Vowed to Sue Hims

Novo Nordisk, the makers of Wegovy, also threatened Hims with a lawsuit, calling the compounded product "an unapproved, inauthentic, and untested knockoff," reports PBS News.

Novo Nordisk and Hims have had a tense past year. In April 2025, the companies announced a partnership to sell Wegovy via the telehealth platform. But by June, the Danish drugmaker announced it was terminating the partnership. Why? Because Hims was selling a compounded version of the injectable product.

"Novo Nordisk is deeply concerned and is continuing to take proactive measures to keep US patients safe from knock-off drugs made with foreign illicit active pharmaceutical ingredients," the company said in a press release at the time.